Our goal is to improve outcomes and reduce healthcare costs by enabling more targeted transfusion of blood products.
We seek to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely information on coagulation status at the point of care. We are developing a next-generation near patient diagnostic platform that provides actionable information to guide the management of critical bleeding. This enables clinicians to choose the right treatment in the right time frame, dramatically improving outcomes. Our innovative in vitro diagnostic platform characterizes hemostasis – the balance between bleeding and clotting – in a variety of acute care clinical settings.
The Quantra Hemostasis Analyzer* is a rapid, easy-to-use, near patient instrument that fully quantifies the treatable components of coagulation and guides the management of critical bleeding. This platform supports a library of disposable test cartridges that aid in the diagnosis of hemostatic defects and inform appropriate therapy.
*The Quantra System is CE marked. Product availability is subject to the fulfillment of regulatory requirements in each market. In the United States, the Quantra System is available for investigational use only. The performance characteristics of this product have not been established.
HemoSonics has been awarded more than $8 million in grants from the following institutions:
- The National Institutes of Health:
- National Heart, Lung and Blood Institute (NHLBI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Cancer Institute (NCI)
- Department of the Air Force
- The Office of Naval Research
- Commonwealth of Virginia
- The Wallace H. Coulter Foundation for Translational Research